| 纯度 | >90%SDS-PAGE. |
| 种属 | Human |
| 靶点 | RPH3AL |
| Uniprot No | Q9UNE2 |
| 内毒素 | < 0.01EU/μg |
| 表达宿主 | E.coli |
| 表达区间 | 1-315aa |
| 氨基酸序列 | MADTIFGSGNDQWVCPNDRQLALRAKLQTGWSVHTYQTEKQRRKQHLSPAEVEAILQVIQRAERLDVLEQQRIGRLVERLETMRRNVMGNGLSQCLLCGEVLGFLGSSSVFCKDCRKKVCTKCGIEASPGQKRPLWLCKICSEQREVWKRSGAWFYKGLPKYILPLKTPGRADDPHFRPLPTEPAEREPRSSETSRIYTWARGRVVSSDSDSDSDLSSSSLEDRLPSTGVRDRKGDKPWKESGGSVEAPRMGFTHPPGHLSGCQSSLASGETGTGSADPPGGPRPGLTRRAPVKDTPGRAPAADAAPAGPSSCLG |
| 预测分子量 | 50.5 kDa |
| 蛋白标签 | His tag N-Terminus |
| 缓冲液 | PBS, pH7.4, containing 0.01% SKL, 1mM DTT, 5% Trehalose and Proclin300. |
| 稳定性 & 储存条件 | Lyophilized protein should be stored at ≤ -20°C, stable for one year after receipt. Reconstituted protein solution can be stored at 2-8°C for 2-7 days. Aliquots of reconstituted samples are stable at ≤ -20°C for 3 months. |
| 复溶 | Always centrifuge tubes before opening.Do not mix by vortex or pipetting. It is not recommended to reconstitute to a concentration less than 100μg/ml. Dissolve the lyophilized protein in distilled water. Please aliquot the reconstituted solution to minimize freeze-thaw cycles. |
以下是关于RPH3AL重组蛋白的示例参考文献(注：部分内容为虚构，建议通过学术数据库核实)：
1. **《RPH3AL重组蛋白在神经分泌中的功能研究》**
- 作者：A. Smith et al.
- 摘要：本研究成功克隆并表达RPH3AL重组蛋白，发现其通过结合Rab3A调控囊泡运输，揭示其在神经内分泌细胞分泌颗粒释放中的关键作用，为相关疾病机制提供新视角。
2. **《RPH3AL基因表达与胞外分泌的分子机制》**
- 作者：B. Lee & C. Zhang
- 摘要：通过体外重组蛋白实验，证明RPH3AL与突触蛋白复合物相互作用，影响钙离子触发的胞吐作用，提示其可能成为内分泌紊乱的治疗靶点。
3. **《RPH3AL重组蛋白的晶体结构解析及功能域分析》**
- 作者：K. Tanaka et al.
- 摘要：首次报道RPH3AL重组蛋白的晶体结构，鉴定出其C端结构域为Rab3效应蛋白结合区域，为设计调控囊泡运输的小分子药物奠定结构基础。
4. **《RPH3AL突变体重组蛋白在肿瘤迁移中的异常表达》**
- 作者：M. Rossi et al.
- 摘要：研究发现RPH3AL重组蛋白在某些癌症细胞中表达异常，其突变体通过破坏Rab信号通路促进肿瘤转移，提示其作为癌症生物标志物的潜力。
建议通过PubMed或Web of Science以“RPH3AL recombinant protein”为关键词检索最新实证研究。
RPH3AL (Rabphilin-3A-like protein) is a calcium-binding protein involved in regulating synaptic vesicle exocytosis and membrane trafficking processes. It shares structural and functional similarities with Rabphilin-3A, a well-characterized effector of Rab3 GTPases. RPH3AL contains two C2 domains (C2A and C2B) that mediate calcium-dependent phospholipid binding and interactions with other synaptic proteins. It plays a role in neurotransmitter release by linking Rab3-associated vesicles to the soluble NSF attachment protein receptor (SNARE) complex machinery. Dysregulation of RPH3AL has been implicated in neurological disorders, including autism spectrum disorders and schizophrenia, where synaptic dysfunction is a key pathological feature.
Recombinant RPH3AL protein is engineered for in vitro studies to elucidate its molecular mechanisms. Produced via heterologous expression systems (e.g., E. coli or mammalian cells), the purified protein retains functional domains necessary for binding Rab3 isoforms, SNARE proteins, and phospholipids. Researchers use it to investigate calcium-triggered conformational changes, vesicle-membrane fusion kinetics, and protein-protein interaction networks. Its recombinant form also aids in structural studies (e.g., X-ray crystallography) to map domain-specific functions. Additionally, it serves as an antigen for antibody development in diagnostic assays. Recent studies explore its potential role in cancer cell exocytosis and chemoresistance, expanding its relevance beyond neuroscience. The availability of recombinant RPH3AL accelerates translational research targeting vesicle trafficking pathways in disease contexts.
×
